Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”
You may also be interested in...
FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio
The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.
FDA Endpoint Development For Pediatric Pulmonary Arterial Hypertension Focuses On Pfizer's Revatio
The standard exercise test is a problem for many pediatric patients, and FDA's Cardiovascular and Renal Drugs Advisory Committee will assess alternatives.
ED Drug Labeling Revised For Potential Risk Of Hearing Loss
FDA identifies 29 postmarketing reports of sudden hearing loss in patients using PDE 5 inhibitors, including Cialis, Levitra and Viagra.